Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS). It has a longer half-life compared to other benzodiazepines.
## Primary Indications
* Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg orally twice daily.
* **Maintenance:** The dose can be increased by 5-10 mg per day every week based on clinical response and tolerability. The maximum recommended maintenance dose is 20 mg orally twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initiation:** 2.5 mg orally twice daily.
* **Maintenance:** The dose can be increased by 2.5-5 mg per day every week based on clinical response and tolerability. The maximum recommended maintenance dose is 10 mg orally twice daily (20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** No specific dosing adjustments are recommended, but caution is advised due to potential for accumulation.
* **Renal Impairment:** No specific dosing adjustments are recommended, but caution is advised.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, constipation, decreased appetite, aggression, irritability, ataxia, vomiting, drooling, upper respiratory tract infection.
* **Serious:** Severe dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms upon abrupt discontinuation, respiratory depression.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam levels.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels.
* **Antiepileptic Drugs (AEDs):** Potential for additive CNS depression; monitor for efficacy and toxicity.
## Monitoring
* Monitor for therapeutic effectiveness and signs of adverse reactions, particularly somnolence and behavioral changes.
* Monitor for signs of withdrawal if discontinuing.
* Consider therapeutic drug monitoring for patients with hepatic or renal impairment, or those on interacting medications, although specific therapeutic ranges are not well-established.
## Clinical Pearls
* Clobazam has a long half-life, which can lead to accumulation, especially with prolonged use or in patients with impaired metabolism.
* Taper the dose gradually when discontinuing to avoid withdrawal symptoms.
* Warn patients about the risk of somnolence and impaired cognitive/motor performance, advising caution with activities requiring alertness.
* Risk of serious skin reactions warrants patient education to report any rash promptly.
---
*Disclaimer: This information is intended for clinical pharmacists and should not be a substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.*
